ArticleTranslational cancer research2020
High expression of
Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 19 citations in OpenAlex.
- PBX3 regulates mast cell parthanatos via TOP2A mediated DNA damage in allergic rhinitis.iScience · 2026Article
- Single cell-RNA sequencing reveal TOP2A as a key driver of hepatocellular carcinoma progression.Scientific reports · 2025Article
- Bioinformatics screened of biomarkers for the prognosis of hepatocellular carcinoma.Cancer biomarkers : section A of Disease markers · 2025Article
- TMT-based proteomic analysis of radiation lung injury in rats.Clinical proteomics · 2024Article
- Immunotherapy and drug sensitivity predictive roles of a novel prognostic model in hepatocellular carcinoma.Scientific reports · 2024Article
- A novel generative adversarial networks modelling for the class imbalance problem in high dimensional omics data.BMC medical informatics and decision making · 2024Article
- Noval ceRNA axis-mediated high expression ofTranslational cancer research · 2023Article
- CD69 serves as a potential diagnostic and prognostic biomarker for hepatocellular carcinoma.Scientific reports · 2023Article
- High expression of TOP2A in hepatocellular carcinoma is associated with disease progression and poor prognosis.Oncology letters · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTopoisomerase (DNA) II alpha (TOP2A) is the up-regulated gene of the chromosome aggregation pathway. This gene encodes DNA topoisomerase, which can control and change the topological state of DNA during transcription and replication, participate in chromosome agglutination, separation, and relieve stress from kinking. Abnormally high expression of TOP2A is often associated with active cell proliferation. In studies of breast cancer, endometrial cancer, and adrenal cancer, it was found that high expression of TOP2A suggested a poor prognosis.
methodsA total of 15 pairs of fresh hepatocellular carcinoma (HCC) specimens and adjacent tissues were assembled, and the difference of TOP2A mRNA and protein expression level between tumor and adjacent tissues was detected by RT-PCR and Western blotting analysis, respectively. A total of 84 HCC paraffin specimens were selected for routine pathological grading. TOP2A expression was detected by immunohistochemistry (IHC). The correlation between TOP2A expression and clinicopathological features and survival time was analyzed.
resultsThe expression of TOP2A mRNA and protein in HCC tumor tissues was significantly higher than that in the adjacent tissues. IHC results indicated that the TOP2A positive rate in tumor tissues was significantly higher than that in adjacent tissues (84.52%, 71/84
conclusionsThe high expression of TOP2A is associated with the invasiveness and poor prognosis of HCC tumors, and, together with liver cirrhosis, can be a prognostic indicator of radical HCC resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.